TAVR has increased the life expectancy of extreme-risk patients, who are above the age of 80 years, have comorbidities, and cannot tolerate open-heart procedures, to nearly 30 months from 11 months. We are still awaiting the results of long-term studies on the life expectancy of moderate- and low-risk patients after a TAVR procedure.